Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

<p>Supplementary Figure S4.</p>

保存先:

書誌詳細
第一著者:	Laura Boucai (15054310) (author)
その他の著者:	Mahesh Saqcena (15054313) (author), Fengshen Kuo (14947443) (author), Ravinder K. Grewal (15054316) (author), Nicholas Socci (15054319) (author), Jeffrey A. Knauf (15008595) (author), Gnana P. Krishnamoorthy (15054322) (author), Mabel Ryder (15054325) (author), Alan L. Ho (15054328) (author), Ronald A. Ghossein (15054331) (author), Luc G.T. Morris (14956461) (author), Venkatraman Seshan (15054334) (author), James A. Fagin (15054337) (author)
出版事項:	2025
主題:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Endocrine-Related Cancers Precision Medicine
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
著者:: Athanasios Bikas (16006076)
出版事項: (2025)

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
著者:: Naveen S. Vasudev (15057037)
出版事項: (2025)

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
著者:: Naveen S. Vasudev (15057037)
出版事項: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
著者:: Yansong Lin (16374208)
出版事項: (2025)

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
著者:: Anna Eriksson (15352461)
出版事項: (2025)

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
著者:: Anna Eriksson (15352461)
出版事項: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
著者:: Katleen Janssens (15053356)
出版事項: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
著者:: Jamunarani Veeraraghavan (16461809)
出版事項: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
著者:: Iris van 't Erve (15054503)
出版事項: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_1919mq89gs4rhjo0r7gph9c5dr